← Search

Excel · study · 2026

Targeting Ewing sarcoma by ex vivo expanded IL1RAP CAR modified TGFbeta imprinted NK cells in combination with IL-15 agonist and anti-GD2 antibody

Listed in NCBI GEO

The prognosis of patients with metastatic Ewing sarcoma (ES) is dismal, largely due to therapy resistance within the tumor microenvironment (TME).

Description

Here, we aim to overcome ES TME resistance to natural killer (NK) cells by a combinatorial immunotherapy approach that enables NK tumor-specific-targeting via chimeric antigen receptor (CAR) against interleukin-1 receptor accessory protein (IL1RAP), circumvents transforming growth factor beta (TGFβ)-mediated immunosuppression by TGFβ-imprinting of NK cells, increases NK cell antibody dependent cellular cytotoxicity (ADCC) via an anti-GD2 antibody dinutuximab, and improves NK cell persistence and ADCC by an IL-15 agonist NKTR-255.

Single-cell-RNAseq analyses of cells from xenograft tumors were performed to identify mechanisms of response/resistance to this combinatorial immunotherapy.

Links

Topics

From keywords
Life Sciences
Inferred from text
Cancer 65%
Provenance · 1 source records, 8 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE31080115 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[disease].local:disease:cancerenrichment · NCBI GEOkeyword-concept-rules@1.0.0title+description (65%)
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[organism].NCBITaxon:10090source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title